All MAC members contribute their expertise to ThyCa on a pro bono basis with no conflict of interest between their professional work and their volunteer work. We are honored to have their involvement on our behalf.
Andrew J Bauer, M.D. is Associate Professor of Pediatrics at the Perelman School of Medicine, University of Pennsylvania, and serves as the director of Children's Hospital of Philadelphia's Thyroid Center. Dr. Bauer retired from the United States Army after 29 years of service, to include two combat tours in Iraq. Dr. Bauer’s clinical and research interests are focused on the study of pediatric thyroid disorders, including hyperthyroidism, hypothyroidism, thyroid nodular disease, thyroid cancer, and familial thyroid tumor syndromes. Dr. Bauer serves as chair of the American Thyroid Association’s (ATA) pediatric thyroid cancer guidelines and as a member of the ATA’s Board of Directors. In 2018, Dr. Bauer served on the World Health Organization, International Agency for Research on Cancer expert group that published guidelines on thyroid screening after nuclear disasters. He has spoken at many ThyCa events.
Keith C. Bible, M.D., Ph.D., is Chair of the Endocrine Malignancies Disease-Oriented Group at the Mayo Clinic Cancer Center in Rochester, Minnesota. He combines clinical practice as a medical oncologist with basic, translational, and clinical research initiatives directed toward the ultimate goal of improving therapies for patients with cancer. He is a member of the Differentiated Thyroid Carcinoma Management Guidelines Task Force and Anaplastic Thyroid Carcinoma Management Guidelines Task Forces of the American Thyroid Association. He received his M.D. degree at the University of Illinois College of Medicine, and his Ph.D. in Organic Chemistry at the University of Illinois at Urbana-Champaign, followed by residency and clinical and research fellowships at the Mayo Clinic.
Naifa L. Busaidy, M.D., is an Endocrinologist and Assistant Professor in the Department of Endocrine Neoplasia and Hormonal Disorders at the University of Texas MD Anderson Cancer Center in Houston, Texas. She is a graduate of Baylor College of Medicine in Houston. She completed postgraduate training at The Royal Hospital and the Sultan Qaboos University Hospital, Oman; Baylor College of Medicine, Houston, Texas; and University of Texas MD Anderson Cancer Center, Houston, Texas. She is the author of numerous research articles and book chapters. Dr. Busaidy is also the recipient of a ThyCa thyroid cancer research grant.
Maria E. Cabanillas, M.D., Endocrinologist, is Assistant Professor in the Department of Endocrine Neoplasia and Hormonal Disorders at The University of Texas MD Anderson Cancer Center, Houston, Texas. Dr. Cabanillas's clinical focus is metastatic thyroid cancer, and her research interests include targeted therapy for metastatic thyroid cancer, as well as supportive care in cancer. She is a graduate of The University of Puerto Rico Medical School. She completed a Residency in Internal Medicine at the University of Texas Health Science Center at Houston, Houston, Texas, and a Fellowship at Baylor College of Medicine, Houston, Texas. She has authored many peer-reviewed journal articles.
Gilbert J. Cote, Ph.D., Researcher, is Professor in the Department of Endocrine Neoplasia and Hormonal Disorders at The University of Texas MD Anderson Cancer Center, Houston, Texas. In 2010 he was named F1000 Faculty Member of the Year. He is co-author of numerous peer-reviewed journal articles on molecular and genetic aspects of medullary thyroid cancer.
Dr. Gianoukakis is a Professor of Medicine of the David Geffen School of Medicine at UCLA and an expert in Thyroid Disorders with particular expertise in Advanced Thyroid Cancer and Clinical Trials for Advanced Thyroid Cancer. He directs the Thyroid Clinic and Thyroid Oncology Clinic at Harbor-UCLA where he also serves as Fellowship Training Program Director. Dr. Gianoukakis is a member of the International Thyroid Oncology Group (ITOG) and the Southern California Thyroid Cancer Consortium (SCThyCC).
Elizabeth G. Grubbs, M.D., is a Surgeon at the University of Texas MD Anderson Cancer Center, in Houston, Texas. She is also Associate Professor, Department of Surgical Oncology. She earned her M.D. at Duke University School of Medicine in North Carolina, followed by postgraduate training at Duke and at the University of Texas MD Anderson Cancer Center. She is author of numerous peer-reviewed original research articles.
Mimi I. Hu, M.D., is an Endocrinologist, Associate Professor, and Deputy Chair of Clinical Operations in the Department of Endocrine Neoplasia and Hormonal Disorders at The University of Texas MD Anderson Cancer Center in Houston, Texas. She graduated from Rice University with a degree in mechanical engineering and obtained her medical degree from the University of Texas - Houston Health Sciences Center. She completed her residency and endocrine fellowship at the Baylor College of Medicine, where she also served as chief medical resident. After completion of her research fellowship at MD Anderson, she joined the faculty in 2007. Dr. Hu's clinical expertise is in the evaluation and treatment of patients with thyroid carcinoma (differentiated and medullary), hereditary endocrine neoplasia disorders, and metabolic bone and mineral disorders. She has been the primary investigator and collaborator on multiple clinical trials evaluating various targeted therapies for advanced thyroid carcinoma. She has published articles and book chapters evaluating the management of medullary thyroid carcinoma, multiple endocrine neoplasia, bone health in cancer patients, endocrine complications of head and neck surgery, and paraneoplastic endocrine disorders.
Joshua P. Klopper, M.D., Endocrinologist, at the Colorado Permanente Medical Group in Denver, CO. His research interests focus on treatment of poorly differentiated thyroid cancer, molecular targets in the nuclear hormone receptor superfamily, activation of retinoid, PPARy, and Vitamin D receptors to inhibit cell growth and potentially induce redifferentiation in aggressive thyroid cancers. He received his medical degree from Emory University School of Medicine, and completed postgraduate training at the University of CO Health Sciences Center. His publication topics include molecular testing for mutations in improving the fine needle aspiration diagnosis of thyroid nodules, DNA profiling analysis of human thyroid cancer cell lines, and inhibiting anaplastic thyroid carcinoma tumor growth.
Barry D. Nelkin Ph.D., is a Laboratory Scientist and Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in Baltimore, Maryland. His interests include Molecular Mechanisms of Thyroid and Lung Cancers. He received his Ph.D., at George Washington University in Washington, D.C. and completed his postdoctoral fellowship at Johns Hopkins Kimmel Cancer Center.
Yuri E. Nikiforov, M.D., Ph.D. is Vice-Chair for Molecular Pathology and Director, Division of Molecular and Genomic Pathology at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania. Dr. Nikiforov oversees the operations of the Molecular and Genomic Pathology laboratory in the Clinical Lab Building; he oversees and participates in clinical sign out in the Division. He also serves at Co-Director, Multidisciplinary Thyroid Center at UPMC. His clinical expertise is in surgical pathology of the thyroid gland and in molecular testing of thyroid other tumors. His research is focused on thyroid cancer genetics and mechanisms of chromosomal rearrangements and other mutations induced by ionizing radiation in thyroid cells and other cell types. He has received the Van Meter Award from the American Thyroid Association, as well as The Endocrine Society;s International Award for Publishing Excellence in The Journal of Clinical Endocrinology & Metabolism.
Eric J. Sherman, M.D., Oncologist, Memorial Sloan-Kettering Cancer Center, New York City, New York, received his medical training at Columbia University College of Physicians and Surgeons, and did his residencies at New York University/Bellevue Medical Center. After a fellowship at the Memorial Sloan Kettering Cancer Center, he joined the Head and Neck Oncology Service there, where he specializes in thyroid cancer and head and neck cancers. Much of his research focuses on targeted therapy in the treatment of thyroid cancers (differentiated thyroid cancer, medullary thyroid cancer, and anaplastic thyroid cancer). Dr. Sherman is board certified in internal medicine and medical oncology.
Jennifer A. Sipos, M.D., is Associate Professor in the Division of Endocrinology, Diabetes and Metabolism at The Ohio State University College of Medicine, Columbus, Ohio. Her clinical and research interests are thyroid cancer, general thyroid disorders, and thyroid physiology. Dr. Sipos has authored numerous journal articles and serves as a member of the National Cancer Institute’s Physician Data Query Cancer Genetics Editorial Board. Following her graduation from medical school, Dr. Sipos completed a residency at Wake Forest University Baptist Medical Center and a fellowship at the University of North Carolina Hospitals.
Ralph Tufano, M.D., M.B.A., F.A.C.S., is the Charles W. Cummings MD Endowed Professor in Otolaryngology – Head and Neck Surgery and the Director of the Division of Head and Neck Endocrine Surgery at Johns Hopkins Medical Institutions. From 2009-2015, he directed the Johns Hopkins Hospital Multidisciplinary Thyroid Tumor Center. His practice focuses exclusively on the surgical management of thyroid and parathyroid diseases. He has authored numerous articles and book chapters and is a national and international speaker on the management of thyroid cancer. His areas of research include novel therapies for thyroid cancer, clinical application of molecular markers, and improving surgical outcomes for patients with thyroid and parathyroid diseases.
Lori J. Wirth, M.D., Medical Oncologist, is Assistant Professor in Medicine at Harvard Medical School and at Massachusetts General Hospital, and clinician in the Head and Neck Oncology Program at the Massachusetts General Hospital Cancer Center, all in Boston, Massachusetts, where thyroid tumors are one of her specialties. Dr. Wirth graduated from Brown University and received her M.D. from Columbia University College of Physicians and Surgeons in New York. She completed a residency in Internal Medicine at New York Presbyterian Hospital and then became a fellow in Medical Oncology at the Dana-Farber Cancer Institute. She is a member of the National Cancer Institute’s Metastatic/Recurrent Disease Task Force/Head and Neck Steering Committee, as well as a Thyroid Cancer Guideline Panel Member of the National Comprehensive Cancer Network. Dr. Wirth has given numerous invited presentations at the regional, national, and international levels and has authored numerous publications. She is also a reviewer for medical journals.